Press Releases :: Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech Appoints Theradex Systems as CRO to Manage Phase I/II Annamycin Trial

Apr 11, 2017

Moleculin Biotech, Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

Apr 3, 2017

Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia

Mar 22, 2017

Moleculin to Present at the 29th Annual Roth Capital Conference

Mar 10, 2017

Moleculin Announces Pricing of $5 Million Underwritten Public Offering

Feb 9, 2017

Moleculin Announces Expanded Scientific Advisory Board

Jan 19, 2017

Moleculin Presents Preclinical Data of Novel Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Dec 13, 2016

Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2016

Nov 21, 2016

Moleculin Announces Positive FDA Guidance Regarding Annamycin IND

Nov 17, 2016

Moleculin Announces Advancement of Preclinical Testing for Brain Tumor Drug WP1122

Oct 26, 2016